Interferon Therapy in Alpha and Delta Variants of Sars-Cov-2: The Dichotomy Between Laboratory Success and Clinical Realities Publisher Pubmed



Alirezaee A^{1, 2} ; Mirmoghtadaei M^{1, 2} ; Heydarlou H^{1, 2} ; Akbarian A³ ; Alizadeh Z^{1, 2}
Source: Cytokine Published:2025

Abstract

The COVID-19 pandemic has caused significant morbidity and mortality worldwide. The emergence of the Alpha and Delta variants of SARS-CoV-2 has led to a renewed interest in using interferon therapy as a potential treatment option. Interferons are a group of signaling proteins produced by host cells in response to viral infections. They play a critical role in the innate immune response to viral infections by inducing an antiviral state in infected and neighboring cells. Interferon therapy has shown promise as a potential treatment option for COVID-19. In this review paper, we review the current knowledge regarding interferon therapy in the context of the Alpha and Delta variants of SARS-CoV-2 and discuss the challenges that must be overcome to translate laboratory findings into effective clinical treatments. © 2024 Elsevier Ltd